© Reuters.
NEW YORK (Reuters) – A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson (NYSE:) of providing drug pricing tools to doctors to induce them to purchase drugs from the company.
The decision by the 2nd U.S. Circuit Court of Appeals in Manhattan restores claims by Adam Hart, a former McKesson business development executive.
MOSCOW, April 5 (Reuters) - Fuel leaked at Russia’s Baltic Sea port of Primorsk, while NORSI oil refinery caught fire...
The numbers are hard to ignore. According to the National Retail Federation, retailers expect ~16% of annual sales to be...
In our usual conversations, “having a virus” means being ill with some kind of infection. The virus is what we...
A trader works on the floor of the New York Stock Exchange (NYSE) at the opening bell in New York...
Founder of Dividend Mantra. Founder of Mr. Free At 33. Co-Founder of Dividends & Income. I started blogging about my journey...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
